ISO 20387:2018 - Biobanking General Requirements Lead Auditor Free Practice Test — 30 Questions

Question 1

During an audit of a biobank\'s adherence to ISO 20387:2018, an auditor is evaluating the effectiveness of the quality management system in managing non-conforming outputs. Which of the following audit activities would provide the most robust evidence of this effectiveness?

Accepted Answer

Reviewing the biobank's documented procedures for identifying, segregating, and disposing of non-conforming biological materials and associated data, and then examining records of actual non-conformities, including their root cause analysis and corrective actions implemented.

Question 2

During an audit of a biobank certified to ISO 20387:2018, an auditor is evaluating the effectiveness of the Quality Management System (QMS). Considering the standard\'s emphasis on ensuring the fitness-for-purpose of biological material, which aspect of the QMS would be the most critical indicator of its overall success in achieving this objective?

Accepted Answer

The extent to which the QMS demonstrably supports the fitness-for-purpose of biological material throughout its entire lifecycle.

Question 3

During an audit of a biobank\'s quality management system, a lead auditor observes that while a novel cell line is stored under cryogenic conditions, the biobank has not established a documented process for periodically assessing the stability of the cryoprotective agent or defined specific criteria for when the agent should be replenished or the samples re-aliquoted. The biobank\'s risk assessment identified the potential for cryoprotective agent degradation over extended storage periods as a low-probability, high-impact risk. What is the most appropriate corrective action for the auditor to recommend to ensure compliance with ISO 20387:2018 requirements for managing risks to biological material integrity?

Accepted Answer

Develop and implement a documented procedure for periodic assessment of cryoprotective agent stability and establish clear criteria for re-aliquoting or replenishment based on stability data.

Question 4

During an audit of a biobank\'s compliance with ISO 20387:2018, an auditor reviews the documented risk management policy. While the policy outlines procedures for identifying and mitigating risks, the auditor\'s findings indicate a lack of concrete evidence demonstrating the biobank\'s proactive engagement in threat modeling and regular vulnerability assessments specifically targeting the digital infrastructure that stores donor information and associated metadata. Considering the auditor\'s role in verifying the effectiveness of the biobank\'s risk management framework, which of the following findings would represent the most significant deficiency in the context of ISO 20387:2018, Clause 7.4.2?

Accepted Answer

Absence of documented evidence of regular, proactive vulnerability assessments and threat modeling for digital assets.

Question 5

During an audit of a biobank\'s compliance with ISO 20387:2018, an auditor is evaluating the effectiveness of the organization\'s risk management framework. The biobank has a documented procedure for identifying potential hazards to biological samples and associated data. However, the auditor observes that this procedure primarily focuses on immediate operational risks, such as equipment failure during processing, and does not systematically address broader, long-term risks like changes in regulatory landscapes or the potential for obsolescence of data storage technologies. Considering the requirements of ISO 20387:2018, which of the following would be the most critical finding for the auditor to report regarding the biobank\'s risk management process?

Accepted Answer

The risk management process fails to comprehensively address a wide spectrum of potential risks throughout the entire lifecycle of biological material and associated data, including strategic and external threats.

Question 6

When assessing the robustness of a biobank\'s quality management system against the requirements of ISO 20387:2018, what is the primary focus for a lead auditor regarding the biobank\'s preparedness for unforeseen external environmental disruptions that could compromise sample viability?

Accepted Answer

Verification that the biobank has established and regularly reviews documented procedures for monitoring and responding to significant changes in international environmental regulations and their potential impact on sample storage and transport.

Question 7

During an audit of a biobank\'s Quality Management System (QMS) in accordance with ISO 20387:2018, an auditor observes laboratory technicians performing sample processing tasks. While the technicians follow documented procedures, they express uncertainty when asked about the broader implications of their actions on sample integrity, the biobank\'s overall quality objectives, and the specific regulatory requirements governing their work beyond immediate procedural steps. What is the most significant QMS deficiency indicated by this observation?

Accepted Answer

Inadequate implementation of personnel competence and awareness requirements, leading to a lack of understanding of their contribution to the QMS and quality objectives.

Question 8

During an audit of a biobank accredited under ISO 20387:2018, an auditor discovers that a batch of cryopreserved human plasma samples, intended for a specific research project requiring a minimum viability of 90%, were found to have a viability of 87% during routine quality control testing. The biobank\'s internal procedure for handling nonconforming outputs dictates segregation and review. However, the auditor notes that the disposition decision for this batch was made by a junior technician without documented justification or supervisory approval, and the samples were subsequently released for a different, less stringent research purpose. Which of the following best reflects the auditor\'s finding regarding the biobank\'s adherence to the QMS requirements for managing nonconforming outputs?

Accepted Answer

The biobank's procedure for managing nonconforming outputs was not adequately implemented, as the disposition decision lacked documented justification and appropriate authorization, failing to ensure control and prevent unintended use.

Question 9

During an audit of a biobank accredited under ISO 20387:2018, an internal audit report highlights a minor nonconformity related to incomplete documentation for sample retrieval requests over a six-month period. The biobank\'s management claims a new procedure has been implemented and staff retrained. As a lead auditor, what is the most critical step to verify the effectiveness of the corrective action?

Accepted Answer

Review a statistically significant sample of retrieval records post-procedure update to confirm complete and accurate documentation, alongside evidence of staff competency validation for the new procedure.

Question 10

During an audit of a biobanking facility, an auditor is assessing the effectiveness of the established Quality Management System (QMS) in relation to the overarching objective of ensuring the fitness for purpose of the biological material and associated data. Which of the following best encapsulates the fundamental requirement for the biobank\'s QMS as stipulated by ISO 20387:2018?

Accepted Answer

The QMS must be comprehensively documented, implemented, and maintained to cover all operational aspects, ensuring the integrity and traceability of biological material and associated data throughout their lifecycle.

Question 11

During an audit of a biobanking facility, an internal investigation report is reviewed detailing a temperature excursion during the transport of a batch of human tissue samples. The report indicates that the temperature monitoring device used for this shipment had an expired calibration certificate. What is the most appropriate action for the lead auditor to take to assess the effectiveness of the biobank\'s quality management system in this context?

Accepted Answer

Extend the audit scope to review the calibration records for all critical equipment used in sample handling and storage to identify any other instances of uncalibrated equipment.

Question 12

During an audit of a biobank\'s quality management system, an auditor discovers a batch of cryopreserved human plasma samples that were inadvertently processed using a thawed aliquot, deviating from the established standard operating procedure for maintaining sample integrity. The biobank\'s internal records indicate that this deviation was noted by a technician but not formally documented as a non-conformity, nor was the affected batch segregated or evaluated for its suitability for future research. The biobank\'s QMS documentation outlines procedures for handling non-conforming outputs, including identification, segregation, and root cause analysis. Considering the principles of ISO 20387:2018 and the auditor\'s role in verifying the effectiveness of the QMS, what is the most appropriate auditor action in this scenario?

Accepted Answer

Document the unaddressed non-conformity as a major non-conformity, requiring the biobank to implement immediate corrective actions and a thorough review of its QMS for handling deviations.

Question 13

During an audit of a biobank accredited under ISO 20387:2018, an auditor observes that the facility utilizes a novel cryopreservation medium for a specific collection of rare plant tissues. While the biobank has internal data suggesting efficacy, there is no independent validation or peer-reviewed publication supporting its use for this particular sample type. The biobank\'s quality management system documentation outlines a process for \"evaluation of new materials,\" but the implementation appears to rely heavily on internal expertise without a formal risk assessment or comparative study against established cryopreservation methods. What is the most significant potential non-conformity an auditor would identify in this scenario regarding the biobank\'s adherence to the standard\'s requirements for sample integrity and quality assurance?

Accepted Answer

Insufficient evidence of process validation for critical materials impacting sample viability.

Question 14

During an audit of a biobank operating under ISO 20387:2018, an auditor is reviewing the procedures for incorporating newly acquired biological material. The biobank has received a batch of tissue samples from a multi-center clinical study. The auditor needs to verify that the biobank\'s internal processes align with the standard\'s requirements for initial handling and identification of incoming specimens. Which of the following aspects of the biobank\'s accessioning process would be the most critical indicator of compliance with the standard\'s fundamental principles for managing biological material?

Accepted Answer

The presence of a documented procedure that assigns a unique, persistent identifier to each biological sample upon receipt and ensures this identifier is linked to comprehensive, accurate metadata.

Question 15

During an audit of a biobank accredited under ISO 20387:2018, an anomaly is discovered concerning a batch of cryopreserved human tissue samples. Records indicate a documented temperature excursion in the storage unit for a period of 12 hours, exceeding the validated operational range. The biobank\'s internal investigation identified a temporary power surge as the cause. What is the most appropriate course of action for the lead auditor to recommend to ensure conformity with the standard\'s requirements for sample integrity and traceability?

Accepted Answer

Mandate a complete re-validation of the storage unit's temperature control system and require a comprehensive risk assessment of all samples stored within that unit, including a scientifically justified evaluation of their fitness-for-purpose, with clear documentation of any affected samples and communication to relevant parties.

Question 16

During an audit of a biobank specializing in the preservation of rare plant genetic resources, a lead auditor is reviewing the implementation of a newly adopted collection protocol for a particularly sensitive species. The protocol involves field collection in remote, high-altitude environments with fluctuating temperature and humidity. The auditor needs to ascertain the biobank\'s adherence to the standard\'s requirements for managing risks associated with the integrity and traceability of biological material. Which of the following findings would represent the most significant non-conformity with ISO 20387:2018?

Accepted Answer

The biobank has a comprehensive, documented risk assessment specifically addressing the unique environmental challenges and potential degradation pathways for this new plant species collection, with corresponding mitigation strategies integrated into the standard operating procedures.

Question 17

During an audit of a biobank\'s compliance with ISO 20387:2018, an auditor is evaluating the effectiveness of the organization\'s risk management framework. Considering the standard\'s emphasis on safeguarding biological material and ensuring operational continuity, which of the following actions by the auditor would most comprehensively demonstrate the verification of this critical requirement?

Accepted Answer

Confirming the existence and consistent application of a documented risk management process that actively identifies and mitigates potential threats to biobank operations and sample integrity.

Question 18

During an audit of a biobank operating under ISO 20387:2018, an auditor discovers a discrepancy in the digital inventory system where a specific aliquot of human plasma, collected from donor ID HPS-789, is recorded as being in freezer unit B-12, rack 3, but upon physical inspection, it is found in freezer unit C-05, rack 1. What is the most critical and immediate action the lead auditor should take to assess the biobank\'s adherence to the quality management system requirements for sample traceability and data integrity?

Accepted Answer

Initiate a detailed trace-back of the specific aliquot's entire lifecycle, from accessioning to its current location, examining all associated records and system entries.

Question 19

When conducting an audit of a biobank accredited to ISO 20387:2018, what is the most fundamental requirement for the effective management of biological material, encompassing its entire lifecycle from acquisition to eventual disposal or use?

Accepted Answer

Implementation of a comprehensive quality management system that integrates risk management, robust documentation, and personnel competency.

Question 20

During an audit of a biobank\'s compliance with ISO 20387:2018, an auditor is reviewing the organization\'s approach to safeguarding sensitive donor genetic data. The biobank has documented a comprehensive risk management plan that includes measures for data encryption, access control lists, and regular security audits. However, the auditor suspects that the implementation of these measures may not be consistently effective in preventing potential unauthorized access or disclosure, which could contravene data protection regulations like GDPR. What specific action should the auditor prioritize to verify the effectiveness of the biobank\'s risk mitigation strategies for donor data privacy?

Accepted Answer

Seek objective evidence demonstrating the operational effectiveness of implemented data security controls and access management protocols.

Question 21

During an audit of a biobank adhering to ISO 20387:2018, an auditor is evaluating the effectiveness of the system for managing its diverse collection of human tissue samples. The biobank utilizes a combination of manual logs and a digital inventory management system. The auditor needs to determine the most critical aspect to verify to ensure the integrity and traceability of the biological material. Which of the following audit findings would most strongly indicate a potential non-conformity related to the core requirements for collection management?

Accepted Answer

The digital inventory system's database schema does not include fields for recording the specific processing reagents used during sample preparation.

Question 22

During an audit of a biobank accredited under ISO 20387:2018, it is discovered that a critical temperature monitoring system for a large cohort of cryopreserved human tissue samples malfunctioned, leading to a documented temperature excursion beyond the established acceptable range for a period of 48 hours. The biobank has initiated corrective actions, including replacing the faulty sensor and recalibrating the backup system. As a lead auditor, what is the most critical aspect to verify regarding the biobank\'s response to this incident to ensure compliance with the standard\'s requirements for quality management and sample integrity?

Accepted Answer

Confirmation that the biobank has conducted a thorough root cause analysis of the monitoring system failure and implemented robust corrective and preventive actions to prevent recurrence, including validation of the new monitoring system's performance.

Question 23

During an audit of a biobank\'s quality management system, an auditor reviews the documented risk assessment for potential sample degradation. The assessment identifies a significant risk related to \"uncontrolled temperature fluctuations impacting sample viability\" and lists the implemented control as \"redundant environmental control systems with continuous monitoring and automated alerts.\" The auditor\'s objective is to verify the effectiveness of this risk mitigation strategy. What specific aspect of the biobank\'s process would represent the most critical finding of non-conformity regarding the implementation of this risk control?

Accepted Answer

Absence of documented evidence of periodic review of the effectiveness of the redundant environmental control systems and a clearly defined protocol for responding to alert escalations.

Question 24

During an audit of a biobank adhering to ISO 20387:2018, an auditor is assessing the effectiveness of the quality management system in managing deviations. Which of the following areas would be the most critical focus for the auditor to verify the biobank\'s compliance with the standard\'s requirements for handling non-conforming outputs?

Accepted Answer

The existence and implementation of documented procedures for the identification, segregation, correction, or disposal of non-conforming biological materials and associated data, along with evidence of their application.

Question 25

During an audit of a biobank accredited under ISO 20387:2018, it is discovered that a critical batch of human plasma samples, intended for long-term storage at $-80^\circ C$, experienced a temporary temperature excursion to $-65^\circ C$ for approximately 12 hours due to a freezer malfunction. The biobank\'s standard operating procedure for temperature deviations requires immediate investigation and assessment of sample integrity. As a lead auditor, what is the primary focus when evaluating the biobank\'s response to this incident, considering the overarching requirements of the standard for quality management and sample traceability?

Accepted Answer

The thoroughness of the root cause analysis and the implementation of corrective actions to prevent recurrence, alongside the documented assessment of the impact on sample viability and the subsequent disposition of the affected samples.

Question 26

During an audit of a biobank\'s operations, an auditor discovers a batch of cryopreserved human tissue samples that were received with incomplete donor consent documentation. The samples are otherwise properly labeled and stored according to established protocols. What is the most significant risk that the lead auditor should identify as a critical finding concerning this situation, considering the requirements of ISO 20387:2018?

Accepted Answer

Potential non-compliance with legal and ethical requirements for donor consent, jeopardizing the future use of the samples.

Question 27

During an audit of a biobank\'s information management system, an auditor is reviewing the procedures for handling sensitive donor genetic data. The biobank has a policy for data anonymization, but the auditor discovers that certain metadata, if cross-referenced with external databases, could potentially re-identify donors. Which of the following actions by the auditor best demonstrates adherence to the principles of ISO 20387:2018 concerning data integrity and confidentiality?

Accepted Answer

Documenting a nonconformity related to the potential for re-identification and requiring the biobank to revise its anonymization protocol to ensure robust de-identification in line with data protection principles.

Question 28

During an audit of a biobank\'s quality management system, an auditor is reviewing the procedures for managing human biological samples and associated data. The biobank has collected samples from diverse international donors, and its operations are subject to varying national data protection laws. Which of the following audit findings would most strongly indicate a potential non-conformity related to the integrity of donor consent and data privacy, requiring further investigation?

Accepted Answer

The biobank's documented procedures for obtaining, storing, and revoking informed consent for sample use and data sharing are comprehensive and demonstrably align with the principles outlined in the biobank's own policy and relevant international privacy regulations.

Question 29

During an audit of a biobanking facility, an auditor is evaluating the effectiveness of the organization\'s quality management system in relation to the lifecycle management of biological material. The facility claims adherence to ISO 20387:2018. What fundamental aspect of the standard\'s requirements must the auditor prioritize to confirm the biobank\'s commitment to maintaining the integrity and traceability of its collections?

Accepted Answer

Verification of a comprehensive, documented quality management system that systematically addresses all stages of biological material handling, personnel competency, risk mitigation, and detailed record-keeping.

Question 30

During an audit of a biobanking facility, an auditor is reviewing the effectiveness of the Quality Management System in ensuring the integrity of stored biological material. The auditor observes that while the biobank has detailed Standard Operating Procedures (SOPs) for sample handling and storage, there is a lack of documented evidence demonstrating the systematic evaluation and mitigation of risks associated with potential environmental fluctuations in the storage facilities. Specifically, the biobank has not established a formal process for assessing the impact of power outages or equipment failures on sample viability, nor has it implemented contingency plans that are regularly tested. Based on the principles of ISO 20387:2018, what is the most critical deficiency in the biobank\'s QMS that the auditor should identify?

Accepted Answer

Inadequate implementation of a risk-based approach to quality management, leading to potential unaddressed threats to sample integrity.

ISO 20387:2018 - Biobanking General Requirements Lead Auditor Free Practice Test — 30 Questions

A lot more is already mapped out

About the ISO 20387:2018 - Biobanking General Requirements Lead Auditor Certification